Psychedelic Medicine SPV

Psychedelic Medicine SPV

Psychedelic Medicine SPV is a London- and San Juan-based investment vehicle focused on the emerging psychedelic therapeutics sector. Its structure as a special purpose vehicle suggests it pools capital from a limited group of investors to back companies developing psilocybin, MDMA, and ketamine-based treatments for mental health conditions. The strategy centers on clinical-stage assets with FDA breakthrough-therapy status — a designation that accelerates regulatory review. The firm targets companies advancing through Phase II and III trials, with an emphasis on post-traumatic stress disorder (PTSD) and treatment-resistant depression. Known exposures in the space include firms like Compass Pathways, which received breakthrough status for psilocybin in depression, and MAPS Public Benefit Corporation, which completed Phase III trials for MDMA-assisted therapy in PTSD. Geographic focus spans North America and Europe, where regulatory frameworks for psychedelic therapies are evolving. Deployment scale and team size are not publicly disclosed. The firm maintains offices in London, San Juan, New York, Lewes (UK), and Brisbane — a geographically distributed footprint unusual for a single-purpose vehicle. No philanthropic foundations or adjacent vehicles are confirmed in public records. In the absence of recent operational events, the firm's posture remains anchored to the regulatory calendar of psychedelic drug approvals. The structural differentiator is the SPV form itself — a finite-life, single-thesis vehicle allowing concentrated bets on a narrow regulatory catalyst. This contrasts with evergreen funds or diversified healthcare managers, aligning capital deployment with discrete drug-approval milestones. Governance and succession structures are not publicly documented.